- Company
- Largest shareholder of Medipost changed to a private equity
- by Chon, Seung-Hyun Mar 18, 2022 05:55am
- The largest shareholder of the bio venture company Medipost will be changed from the founder and CEO Yoon-sun Yang to a private equity consortium. Medipost plans to receive an investment of approximately &8361;140 billion from a private equity fund to invest in its cell and gene therapy business. On the 17th, Medipost announced that it h
- Company
- Multinational pharmaceutical companies are changing logos
- by Mar 18, 2022 05:55am
- Organon Korea returns after 13 years of absence with a new logo, "Women's Health" starts anew. Multinational pharmaceutical companies are trying to transform their image with new logos. Pfizer entered the unexplored area of mRNA and changed its logo in about 70 years. Sanofi also emphasized "one Sanofi" as an integrated brand logo. Analysts s
- Company
- Same ‘one-shot’ but different? Zolgensma reimb slow
- by Eo, Yun-Ho Mar 17, 2022 05:59am
- Although both drugs are from the same pharmaceutical company and are both one-shot, high-priced drugs, the two drugs are showing a stark difference in their results. Discussions on the reimbursement listing for Novartis Korea’s Zolgensma (onasemnogene abeparvovec) is not progressing so smoothly. The company had applied for the reimbursem
- Company
- Molnupiravir can be supplied on the day of approval
- by Mar 17, 2022 05:58am
- MSD is trying to contribute a lot to overcoming the COVID-19 pandemic. Molnupiravir is fully prepared to be supplied on the same day as soon as it is approved. Kevin Peters, CEO of MSD Korea, made the remarks at a press conference held on the 16th. MSD developed the COVID-19 treatment Molnupiravir last year and received the U.S. Food and
- Company
- Verzenio makes "bid with verified data” against Ibrance
- by Mar 17, 2022 05:58am
- The breast cancer treatment ‘Verzenio’ is working hard to expand its market. Although it is a latecomer in the CDK 4/6 inhibitor market, Lilly is showing confidence that it can bring different results from other previous treatments. In fact, Verzenio is pioneering the base of use of CDK4/6 inhibitors from metastatic breast cancer to early b
- Company
- Drug-resistant TB drug Dovprela applies for reimbursement
- by Eo, Yun-Ho Mar 16, 2022 05:57am
- ‘Dovprela,’ the first new drug introduced in the field of tuberculosis in 50 years, is attempting reimbursement listing in Korea. According to industry sources, Viatris Korea has submitted an application for the reimbursement listing of its multi-drug resistant tuberculosis treatment, Dovprela (pretomanid). Dovprela, which was first
- Company
- Whether companies give up developing COVID-19 vaccines
- by Kim, Jin-Gu Mar 16, 2022 05:57am
- Domestic pharmaceutical companies are divided over the development of the COVID-19 vaccine. After the introduction of Pfizer, Moderna Vaccine, some companies stopped developing due to reduced commerciality and difficulties in recruiting clinical participants. Companies that are newly developing in preparation of the coronavirus are steadily
- Company
- Exon 20 insertion targeting Exkivity comes to Korea
- by Eo, Yun-Ho Mar 15, 2022 05:58am
- Takeda’s new lung cancer drug ‘Exkivity’ is coming to Korea. According to industry sources, Takeda Pharmaceuticals Korea recently submitted an application for the marketing authorization of ‘Exkivity (mobocertinib).’ The drug is expected to be approved within the year at the earliest. Exkivity was approved in the US in September
- Company
- Samsung·Celltrion speeds up dev of follow-on similars
- by Ji Yong Jun Mar 15, 2022 05:58am
- Celltrion and Samsung Bioepis’s follow-on biosimilars are gaining momentum in the global market. A total of 11 biosimilars from the two companies are being prepared for their launch into the global market. According to the industry on the 14th, Celltrion’s Avastin biosimilar is awaiting approval in the US and European market this year.
- Company
- Pharma·Biopharmas make or break COVID-19 CMO deals
- by Ji Yong Jun Mar 14, 2022 05:51am
- Domestic pharmaceutical companies are experiencing mixed results regarding their CMO businesses for COVID-19 vaccines. Samsung Biologics and SK Bioscience are already in the process of manufacturing COVID-19 vaccines. On the other hand, GC Pharma and Huons Global gave up their COVID-19 vaccine CMO business. In addition, uncertainties continu
